News about Clinical Trials

Roche's Gazyva/Gazyvaro Shows Positive Results for Systemic Lupus Erythematosus in Phase III trials

The ALLEGORY study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva/Gazyvaro versus standard therapy.

Clinical Trials | 05/11/2025 | By Dineshwori

Johnson & Johnson MedTech Confirms Durability of IVL in Complex Below-the-Knee Lesions in PAD Patients

Johnson & Johnson MedTech has released the one-year results of its DISRUPT BTK II study, reaffirming the safety and durability of the Shockwave Peripheral Intravascular Lithotripsy (IVL) System for the treatment of calcified below-the-knee (BTK) lesions in patients with peripheral artery disease (PA

Clinical Trials | 04/11/2025 | By Dineshwori

GC Biopharma's Anthrax Vaccine Shows Safety and Immunogenicity in Phase 2 trial

The Phase 2 clinical trial demonstrated that the anthrax vaccine by GC Biopharma elicited antibodies that neutralised the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.

Clinical Trials | 03/11/2025 | By Dineshwori

WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension

Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.

Clinical Trials | 29/10/2025 | By Dineshwori

Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis

Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.

Clinical Trials | 28/10/2025 | By Dineshwori

Sanofi's Efdoralprin Alfa Meets Key Goals in Phase-II AATD Emphysema Study

Efdoralprin Alfa was previously granted fast track and Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of AATD Emphysema. It is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Clinical Trials | 27/10/2025 | By Dineshwori

Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC

Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.

Clinical Trials | 24/10/2025 | By Dineshwori

METiS TechBio's AI-Designed Drug MTS-004 Completes Phase III Trial for Pseudobulbar Affect

METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, has announced that its small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial.

Clinical Trials | 24/10/2025 | By Dineshwori

Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes

Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.

Clinical Trials | 16/10/2025 | By Dineshwori |  145

Pfizer Reports Positive Phase 3 Results for TUKYSA Combination in First-Line HER2+ Metastatic Breast Cancer

Pfizer has announced positive topline results from its Phase 3 HER2CLIMB-05 trial evaluating TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for patients with HER2-positive (HER2+) metastatic breast cancer (MBC).

Clinical Trials | 15/10/2025 | By Dineshwori